Skip to content
drillr.ai
Sign up

GILD

GILEAD SCIENCES, INC.

NASDAQ · Healthcare · Drug Manufacturers - General · US

$172.31
+2.89%
Ask drillr

  • Nov 3, 2026, 23:36 UTC

    The U.S. Food and Drug Administration approved a generic injectable version of lenacapavir for HIV prevention on November 2, 2026.

    Source:

  • Nov 2, 2026, 13:30 UTC

    Gilead Sciences announced that it will participate in HIV Glasgow 2026 from November 8–11 and present results from more than 50 studies, including late-breaking clinical data and real-world evidence.

    Source:

  • Oct 29, 2026, 22:36 UTC

    GILEAD SCIENCES, INC. reported quarterly earnings of $2.55 per share, above the Zacks Consensus Estimate of $2.17 and compared with $2.47 per share a year earlier.

    Source:

  • Oct 29, 2026, 20:02 UTC

    Gilead Sciences announced its third-quarter 2026 results of operations.

    Source:

  • Oct 26, 2026, 15:30 UTC

    GILEAD SCIENCES, INC. agreed to acquire an experimental immune disease drug from PepStar Therapeutics for nearly $1.3 billion in cash.

    Source:

  • Oct 22, 2026, 23:12 UTC

    GILEAD SCIENCES, INC. agreed to pay $45 million to settle Texas allegations that it paid kickbacks that improperly influenced prescriptions covered by Texas Medicaid.

    Source:

  • Oct 22, 2026, 12:00 UTC

    Gilead Sciences announced that it will present clinical and real-world evidence on primary biliary cholangitis and chronic hepatitis delta virus infection at The Liver Meeting 2026.

    Source:

  • Oct 22, 2026, 10:45 UTC

    BioNTech SE and GILEAD SCIENCES, INC. announced a clinical trial collaboration and supply agreement to evaluate pumitamig with sacituzumab govitecan as first-line treatment for locally advanced or metastatic PD-L1-low or -negative triple-negative breast cancer.

    Source:

  • Oct 21, 2026, 23:01 UTC

    GILEAD SCIENCES, INC. shares fell 1.88% to $153.57 from the prior session's close.

    Source:

  • Oct 19, 2026, 12:00 UTC

    Gilead Sciences said it will present 28 research presentations, including two oral presentations, at Innoviva, Inc. 2026 on HIV treatment, prevention, and emerging antiviral programs.

    Source:

  • Oct 19, 2026, 10:41 UTC

    GILEAD SCIENCES, INC. reported that its pill succeeded in a mid-stage trial for bowel disease.

    Source:

  • Oct 19, 2026, 08:35 UTC

    GILEAD SCIENCES, INC. reported Phase 2 results showing its emvistegrast treatment produced a 23% placebo-adjusted clinical remission rate in patients with moderate to severe ulcerative colitis after a 200 mg daily dose for 12 weeks.

    Source:

  • Oct 15, 2026, 23:00 UTC

    GILEAD SCIENCES, INC. closed at $157.48, up 2.57% from the previous trading session.

    Source:

  • Oct 14, 2026, 22:45 UTC

    The listed top gainers included Perrigo, up 3.77%; GILEAD SCIENCES, INC., up 3.8%; Kroger, up 3.87%; BRISTOL MYERS SQUIBB CO, up 4.61%; and UNITEDHEALTH GROUP INC, up 4.73%.

    Source:

  • Oct 14, 2026, 16:58 UTC

    Vir Biotechnology, Inc. and GILEAD SCIENCES, INC. announced a collaboration to create three T-cell engagers for treating solid tumors.

    Source:

  • Oct 14, 2026, 12:42 UTC

    Vir Biotechnology entered into a stock purchase agreement to issue 1,765,486 shares of common stock to Gilead Sciences for $14.16 per share, or $25 million in total.

  • Oct 7, 2026, 06:45 UTC

    COGNIZANT TECHNOLOGY SOLUTIONS CORP extended its partnership with GILEAD SCIENCES, INC. for five years to support selected technology programs, including DevOps and AI-enabled workflows.

    Source:

  • Oct 5, 2026, 11:00 UTC

    Nurix Therapeutics and Gilead Sciences agreed to extend the research term for an undisclosed oncology program within their ongoing strategic collaboration by an additional two years.

    Source:

  • Oct 2, 2026, 22:50 UTC

    Gilead Sciences (GILD) shares fell 1.87% to close at $144.74 on the most recent trading day.

    Source:

  • Oct 1, 2026, 12:35 UTC

    Vir Biotechnology, Inc. appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026.

  • Sep 30, 2026, 22:00 UTC

    Gilead Sciences will supply its HIV prevention drug lenacapavir to 24 low- and middle-income countries through partnerships with the Global Fund and PEPFAR, as announced by CEO Daniel O'Day at the Clinton Global Initiative conference in New York.

    Source:

  • Sep 23, 2026, 12:17 UTC

    Justin Gunn was appointed President, Endocrinology at Corcept Therapeutics effective October 1, 2026.

  • Sep 16, 2026, 14:30 UTC

    Gilead Sciences committed to advancing a technology-transfer process in Brazil aimed at enabling future local production of lenacapavir.

    Source:

  • Sep 16, 2026, 14:30 UTC

    The Pan American Health Organization (PAHO) announced an agreement with Gilead Sciences to make lenacapavir available for HIV prevention in 14 Latin American and Caribbean countries through its Regional Revolving Funds.

    Source:

  • Sep 16, 2026, 12:32 UTC

    Gilead Sciences extended six royalty-free licensing agreements covering 120 countries.

    Source:

  • Sep 13, 2026, 01:45 UTC

    Merck's Keytruda was evaluated as monotherapy and in combination with Trodelvy in the Merck-sponsored Evoke-03/Keynote-D46 phase 3 trial in previously untreated PD-L1-high non-small cell lung cancer, with results presented at the 2026 World Conference on Lung Cancer.

    Source:
Page 1Next →